 |
PARISJune 2, 2026 /PRNewswire/ — On the eve of SNMMI 2026, DOSIsoft, a leading provider of dosimetry software in radiation oncology and nuclear medicine, today announced the establishment of DOSIsoft Theranostics, a specialized entity focused on developing theranostic software to drive broader routine clinical applications.
As a fully independent company dedicated to theranostics, DOSIsoft Theranostics is uniquely positioned to serve the entire clinical and industrial ecosystem as a neutral, trusted software partner, with strategic autonomy to pursue its own innovation, partnerships, and long-term investments.
By combining diagnosis with targeted therapy to achieve truly personalized treatment, theranostics is entering a new phase of clinical and industrial expansion. Leveraging over two decades of DOSIsoft expertise, DOSIsoft Theranostics will accelerate innovative software solutions to support radiopharmaceutical therapies and the evolution of nuclear medicine, aiming for more robust quantitative imaging, AI-driven workflows, and personalized treatment.
The entity focuses on routine clinical applications, establishing personalized patient treatment monitoring, a field increasingly encompassing numerous imaging modalities, hospital departments, continuous treatment cycles, and combination therapy regimens. Advanced software tools and specialized scientific knowledge also contribute to advancing research and clinical innovation.
At the core of DOSIsoft Theranostics is PLANET®, DOSIsoft’s flagship theranostic software platform. Originating from DOSIsoft’s deep roots in external beam radiation therapy planning, PLANET® has evolved into a comprehensive platform featuring advanced voxel-based multi-radionuclide dosimetry capabilities and full multi-modality DICOM interoperability. PLANET® is FDA 510(k) cleared and CE marked, deployed in numerous leading hospitals and academic centers worldwide, and employs a vendor-neutral architecture, giving clinicians the flexibility to support various clinical workflows and treatment strategies.
Marc Uszynski, CEO of DOSIsoft, stated: “Creating a specialized theranostics entity reflects DOSIsoft’s long-term commitment to this rapidly evolving field. DOSIsoft Theranostics thus gains strategic focus and agility to accelerate innovation, forge new partnerships, and expand theranostic applications globally.“
DOSIsoft Theranostics will participate in SNMMI 2026 (Booth 1358).
About DOSIsoft
Founded in 2002, DOSIsoft is a market leader in dosimetry software for radiation oncology and nuclear medicine, dedicated to improving cancer treatment quality and enhancing patient safety. With over 1,000 installations in more than 800 hospital centers across 80 countries, DOSIsoft provides advanced solutions for radiotherapy quality assurance, theranostics, and personalized dosimetry. A spin-off from Gustave Roussy and Institut Curie, DOSIsoft collaborates closely with leading cancer centers worldwide to drive continuous innovation. DOSIsoft is a participating partner in the European Thera4Care project (a theranostic ecosystem for personalized care).